HONG KONG – The U.S. FDA has, for the first time ever, approved the use of a biologic product made by a Chinese company in U.S. investigational new drug trials.
HONG KONG – Ambrx Inc. and Zhejiang Hisun Pharmaceuticals Co. Ltd. (SH:600267) inked a deal to develop and commercialize bispecifics based on Ambrx's research with an aim to develop new oncology therapies.
HONG KONG – Ambrx Inc. and Zhejiang Hisun Pharmaceuticals Co. Ltd. (SH:600267) inked a deal to develop and commercialize bispecifics based on Ambrx's research with an aim to develop new oncology therapies.
HONG KONG – Indian pharmaceutical company Lupin Ltd. (BSE:500257, NSE:LUPIN) plans to launch a new company dedicated to biosimilars in Japan with its Japanese partner, Toyama-based pharmaceutical Yoshindo Inc.
HONG KONG – An Indian pharmaceutical company said it is still exporting its products to Vietnam as usual, disputing reports that it had been one of some four-dozen companies allegedly banned from the growing Southeast Asian market.
HONG KONG – Indian pharmaceutical company Lupin Ltd. (BSE:500257, NSE:LUPIN) plans to launch a new company dedicated to biosimilars in Japan with its Japanese partner, Toyama-based pharmaceutical Yoshindo Inc.
HONG KONG – An Indian pharmaceutical company said it is still exporting its products to Vietnam as usual, disputing reports that it had been one of some four-dozen companies allegedly banned from the growing Southeast Asian market.
HONG KONG – The CFDA gave the green light to Chongqing Zhifei Biological Products Co. Ltd. (SZ:300122) to launch its joint vaccine against group A and C meningococcus and haemophilus influenzae type B (AC-Hib). Zhifei's subsidiary, Beijing Zhifei Lvzhu Biopharmaceutical Co., developed the vaccine that aims to prevent infectious diseases such as meningitis, pneumonia, septicemia, cellulitis, arthritis and epiglottitis caused by group A and C meningococcus as well as type b haemophilus influenzae (Hib).
HONG KONG – A Chinese investment company focused on health care has secured a third fund to invest $188 million in pharmaceuticals, medical technology, health care services and biotech companies.
HONG KONG – Hutchison China Meditech Ltd. (LSE:HCM) and Sinopharm Group Co. Ltd. (SEHK:1099) have gained regulatory approval for their new joint venture that will provide sales, distribution and marketing services to pharmaceutical companies in China.
